Skip to content
sellModerate cluster of 310b5-1 plan

Max Rosett sold $1.1M of IMNM

Chief Financial Officer at Immunome Inc.. 60,000 shares at an average of $18.23, traded Jun 15, 2026, filed Jun 17, 2026.

Warning score
47
Value
$1.1M
60,000 shares
Holdings after
54,037
-53% from before
From 52-week low
+115%
low $8.40, close $18.07
From 52-week high
-33%
high $26.97, as of Jun 15, 2026

Score components

  • Role
    CFO
    +22
  • Trade size
    $1.1M at market
    +25
  • Share of holdings sold
    Sold 53% of holdings
    +20
  • Cluster
    3 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

IMNMOct 12, 2026 · close 19.15
Since filing Jun 17, 2026: +3.3%SPY +5.5% · excess -2.2%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001994071-26-000004, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jun 15, 2026MOption exercise
Common Stock10b5-1
+60,000$1.05$63k114,037Jun 17, 2026
Jun 15, 2026SOpen-market sale
Common Stock10b5-1
-60,000$18.23$1.1M54,037Jun 17, 2026
Jun 15, 2026MOption exercise
Stock Option (right to buy)derivative10b5-1
-60,000$0.00$00Jun 17, 2026

Related signals

Other insiders at Immunome Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
0Weak
IMNMsell10b5-1
Immunome Inc.
Jack Higgins
Chief Scientific Officer
$334k
13,200 shares
-17%
48Moderate
IMNMsell 210b5-1
Immunome Inc.
Isaac Barchas
director
$2.2M
83,464 shares
-115%
37Weak
IMNMsell 210b5-1
Immunome Inc.
Isaac Barchas
director
$940k
36,088 shares
-33%
33Weak
IMNMsell 210b5-1
Immunome Inc.
Kinney Horn
CHIEF BUSINESS OFFICER
$2.3M
90,616 shares
-100%
20Weak
IMNMsell 310b5-1
Immunome Inc.
Kinney Horn
CHIEF BUSINESS OFFICER
$27k
1,092 shares
-100%
45Moderate
IMNMsell 310b5-1
Immunome Inc.
Isaac Barchas
director
$2.4M
100,000 shares
-48%
40Moderate
IMNMsell 310b5-1
Immunome Inc.
Robert Lechleider
Chief Medical Officer
$1.2M
55,000 shares
-78%
45Moderate
IMNMsell 310b5-1
Immunome Inc.
Isaac Barchas
director
$4.4M
201,050 shares
-49%
40Moderate
IMNMsell 410b5-1
Immunome Inc.
Robert Lechleider
Chief Medical Officer
$1.1M
55,000 shares
-78%
46Moderate
IMNMbuy
Immunome Inc.
Jean Jacques Bienaime
director
$204k
10,500 shares
+32%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Max Rosett sold $1.1M of IMNM | InsiderTell